Download
10549_2024_Article_7207.pdf 612,65KB
WeightNameValue
1000 Titel
  • Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer
1000 Autor/in
  1. Hatzipanagiotou, Maria Eleni |
  2. Pigerl, Miriam |
  3. Gerken, Michael |
  4. Räpple, Sophie |
  5. Zeltner, Verena |
  6. Hetterich, Madeleine |
  7. Ugocsai, Peter |
  8. Inwald, Elisabeth Christine |
  9. Klinkhammer-Schalke, Monika |
  10. Ortmann, Olaf |
  11. Seitz, Stephan |
1000 Verlag
  • Springer US
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-01-19
1000 Erschienen in
1000 Quellenangabe
  • 204(3):607-615
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s10549-023-07207-4 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959785/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose</jats:title> <jats:p>The optimal time to initiation of adjuvant chemotherapy (TTAC) for triple negative breast cancer (TNBC) patients is unclear. This study evaluates the association between TTAC and survival in TNBC patients.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>We conducted a retrospective study using data from a cohort of TNBC patients diagnosed between January 1, 2010 to December 31, 2018, registered in the Tumor Centre Regensburg was conducted. Data included demographics, pathology, treatment, recurrence and survival. TTAC was defined as days from primary surgery to first dose of adjuvant chemotherapy. The Kaplan–Meier method was used to evaluate impact of TTAC on overall survival (OS) and 5-year OS.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>A total of 245 TNBC patients treated with adjuvant chemotherapy and valid TTAC data were included. Median TTAC was 29 days. The group receiving systemic therapy within 22 to 28 days after surgery had the most favorable outcome, with median OS of 10.2 years. Groups receiving systemic therapy between 29–35 days, 36–42 days, and more than 6 weeks after surgery had significantly decreased median survival, with median OS of 8.3 years, 7.8 years, and 6.9 years, respectively. Patients receiving therapy between 22–28 days had significantly better survival compared to those receiving therapy between 29–35 days (p = 0.043), and patients receiving therapy after 22–28 days also demonstrated significantly better survival compared to those receiving therapy after more than 43 days (p = 0.033).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Timing of adjuvant systemic therapy can influence OS in TNBC patients. Efforts should be made to avoid unnecessary delays in administering chemotherapy to ensure timely initiation of systemic therapy and optimize patient outcomes.</jats:p> </jats:sec>
1000 Sacherschließung
lokal Female [MeSH]
lokal Timing of adjuvant chemotherapy
lokal Triple Negative Breast Neoplasms/pathology [MeSH]
lokal Humans [MeSH]
lokal Retrospective Studies [MeSH]
lokal Epidemiology
lokal Neoplasm Staging [MeSH]
lokal Triple negative breast cancer
lokal Population-based cancer registry
lokal Chemotherapy, Adjuvant/methods [MeSH]
lokal Outcomes in TNBC
lokal Routine practice data
lokal Combined Modality Therapy [MeSH]
lokal Breast Neoplasms/pathology [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-2831-4282|https://frl.publisso.de/adhoc/uri/UGlnZXJsLCBNaXJpYW0=|https://frl.publisso.de/adhoc/uri/R2Vya2VuLCBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/UsOkcHBsZSwgU29waGll|https://frl.publisso.de/adhoc/uri/WmVsdG5lciwgVmVyZW5h|https://frl.publisso.de/adhoc/uri/SGV0dGVyaWNoLCBNYWRlbGVpbmU=|https://frl.publisso.de/adhoc/uri/VWdvY3NhaSwgUGV0ZXI=|https://frl.publisso.de/adhoc/uri/SW53YWxkLCBFbGlzYWJldGggQ2hyaXN0aW5l|https://frl.publisso.de/adhoc/uri/S2xpbmtoYW1tZXItU2NoYWxrZSwgTW9uaWth|https://frl.publisso.de/adhoc/uri/T3J0bWFubiwgT2xhZg==|https://frl.publisso.de/adhoc/uri/U2VpdHosIFN0ZXBoYW4=
1000 Hinweis
  • DeepGreen-ID: e6c2a4ec30dc454d94352242bac5b887 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Universitätsklinikum Regensburg |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Universitätsklinikum Regensburg |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6522803.rdf
1000 Erstellt am 2025-07-06T17:11:58.060+0200
1000 Erstellt von 322
1000 beschreibt frl:6522803
1000 Zuletzt bearbeitet 2025-07-29T17:37:06.843+0200
1000 Objekt bearb. Tue Jul 29 17:37:06 CEST 2025
1000 Vgl. frl:6522803
1000 Oai Id
  1. oai:frl.publisso.de:frl:6522803 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source